{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:48:22Z","timestamp":1788536902408,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,3,14]],"date-time":"2020-03-14T00:00:00Z","timestamp":1584144000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,14]],"date-time":"2020-03-14T00:00:00Z","timestamp":1584144000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s11899-020-00572-7","type":"journal-article","created":{"date-parts":[[2020,3,14]],"date-time":"2020-03-14T06:02:42Z","timestamp":1584165762000},"page":"125-129","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Polatuzumab Vedotin: a New Target for B Cell Malignancies"],"prefix":"10.1007","volume":"15","author":[{"given":"Yun","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine S.","family":"Diefenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,14]]},"reference":[{"key":"572_CR1","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13045-019-0786-6","volume":"12","author":"B Yu","year":"2019","unstructured":"Yu B, Liu D. Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma. J Hematol Oncol. 2019;12:94.","journal-title":"J Hematol Oncol"},{"key":"572_CR2","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/1096-8652(200008)64:4<275::AID-AJH7>3.0.CO;2-Y","volume":"64","author":"G D'Arena","year":"2000","unstructured":"D'Arena G, Musto P, Cascavilla N, Dell'Olio M, Di Renzo N, Carotenuto M. Quantitative flow cytometry for the differential diagnosis of leukemic B-cell chronic lymphoproliferative disorders. Am J Hematol. 2000;64:275\u201381.","journal-title":"Am J Hematol"},{"key":"572_CR3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1053\/j.seminhematol.2015.01.008","volume":"52","author":"RM Young","year":"2015","unstructured":"Young RM, Shaffer AL 3rd, Phelan JD, Staudt LM. B-cell receptor signaling in diffuse large B-cell lymphoma. Semin Hematol. 2015;52:77\u201385.","journal-title":"Semin Hematol"},{"key":"572_CR4","unstructured":"The Human Protein Atlas. CD79B. 2019, at https:\/\/www.proteinatlas.org\/ENSG00000007312-CD79B\/pathology.)"},{"key":"572_CR5","unstructured":"Polivy\u2122 (Polatuzumab vedotin-piiq) for injection, for intravenous use: Highlights of Prescribing Information. 2019."},{"key":"572_CR6","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/S1470-2045(15)70128-2","volume":"16","author":"MCA Palanca-Wessels","year":"2015","unstructured":"Palanca-Wessels MCA, Czuczman M, Salles G, Assouline S, Sehn LH, Flinn I, et al. Safety and activity of the anti-CD79B antibody\u2013drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol. 2015;16:704\u201315.","journal-title":"Lancet Oncol"},{"key":"572_CR7","doi-asserted-by":"publisher","first-page":"e19070\u2013e","DOI":"10.1200\/JCO.2016.34.15_suppl.e19070","volume":"34","author":"K Hatake","year":"2016","unstructured":"Hatake K, Kinoshita T, Terui Y, et al. A phase I pharmacokinetic and safety study of polatuzumab vedotin in Japanese patients with relapsed\/refractory b-cell non-Hodgkin lymphoma: A comparison with non-Japanese DCS4968g study. J Clin Oncol. 2016;34:e19070\u2013e.","journal-title":"J Clin Oncol"},{"key":"572_CR8","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/S2352-3026(19)30026-2","volume":"6","author":"F Morschhauser","year":"2019","unstructured":"\u2022 Morschhauser F, Flinn IW, Advani R, et al. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Lancet Haematol. 2019;6:e254\u2013e65 The ROMULUS trial was the first phase II trial to evaluate the combination of pola with a CD20 monoclonal antibody. With the ORR of 54% and 21% CR rate in the DLBCL population, this trial solidified the pola's role as a viable therapeutic agent in the treatment of R\/R DLBCL.","journal-title":"Lancet Haematol"},{"key":"572_CR9","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1007\/s12325-016-0451-1","volume":"34","author":"K Tobinai","year":"2017","unstructured":"Tobinai K, Klein C, Oya N, Fingerle-Rowson G. A review of Obinutuzumab (GA101), a novel type II anti-CD20 monoclonal antibody, for the treatment of patients with B-cell malignancies. Adv Ther. 2017;34:324\u201356.","journal-title":"Adv Ther"},{"key":"572_CR10","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1182\/blood.V128.22.622.622","volume":"128","author":"T Phillips","year":"2016","unstructured":"Phillips T, Brunvand M, Chen A, et al. Polatuzumab Vedotin Combined with Obinutuzumab for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: Preliminary Safety and Clinical Activity of a Phase Ib\/II Study. Blood. 2016;128:622.","journal-title":"Blood"},{"key":"572_CR11","unstructured":"Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2019:JCO.19.00172."},{"key":"572_CR12","doi-asserted-by":"publisher","first-page":"4081","DOI":"10.1182\/blood-2019-123449","volume":"134","author":"LH Sehn","year":"2019","unstructured":"\u2022\u2022 Sehn LH, Matasar MJ, Flowers CR, et al. Polatuzumab Vedotin plus Bendamustine with rituximab in relapsed\/refractory diffuse large B-cell lymphoma: updated results of a phase Ib\/II randomized study. Blood. 2019;134:4081 The randomized phase II trial of this study led to the first FDA approval for pola in combination with bendamustine and rituximab for the treatment of patients with R\/R DLBCL who have received at least two prior lines of thearpy.","journal-title":"Blood"},{"key":"572_CR13","first-page":"2821","volume":"130","author":"LH Sehn","year":"2017","unstructured":"Sehn LH, Herrera AF, Matasar MJ, et al. Addition of Polatuzumab Vedotin to Bendamustine and Rituximab (BR) Improves Outcomes in Transplant-Ineligible Patients with Relapsed\/Refractory (R\/R) Diffuse Large B-Cell Lymphoma (DLBCL) Versus BR Alone: Results from a Randomized Phase 2 Study. Blood. 2017;130:2821.","journal-title":"Blood"},{"key":"572_CR14","unstructured":"FDA approves polatuzumab vedotin-piiq for diffuse large B-cell lymphoma. 2019. at https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-polatuzumab-vedotin-piiq-diffuse-large-b-cell-lymphoma."},{"key":"572_CR15","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S1470-2045(19)30091-9","volume":"20","author":"H Tilly","year":"2019","unstructured":"Tilly H, Morschhauser F, Bartlett NL, Mehta A, Salles G, Haioun C, et al. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b\u20132 study. Lancet Oncol. 2019;20:998\u20131010.","journal-title":"Lancet Oncol"},{"key":"572_CR16","doi-asserted-by":"publisher","first-page":"TPS7571","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS7571","volume":"37","author":"H Tilly","year":"2019","unstructured":"\u2022 Tilly H, Flowers C, Friedberg JW, et al. POLARIX: a phase 3 study of polatuzumab vedotin (pola) plus R-CHP versus R-CHOP in patients (pts) with untreated DLBCL. J Clin Oncol. 2019;37:TPS7571\u2013TPS The POLARIX trial is the first phase III trial of pola in combiation with chemoimmunotherapy in newly diagnosed DLBCL patientsResults of the POLARIX study are eagerly awaited.","journal-title":"J Clin Oncol"},{"key":"572_CR17","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1182\/blood.V128.22.1856.1856","volume":"128","author":"A Forero-Torres","year":"2016","unstructured":"Forero-Torres A, Kolibaba KS, Lamy T, Jones S, Lee C, Sharman J. Polatuzumab Vedotin Combined with Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone (G-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib\/II Dose-Escalation Study. Blood. 2016;128:1856.","journal-title":"Blood"},{"key":"572_CR18","doi-asserted-by":"publisher","first-page":"e429","DOI":"10.1016\/S2352-3026(19)30089-4","volume":"6","author":"F Morschhauser","year":"2019","unstructured":"Morschhauser F, Le Gouill S, Feugier P, et al. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study. Lancet Haematol. 2019;6:e429\u2013e37.","journal-title":"Lancet Haematol"},{"key":"572_CR19","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1200\/JCO.2014.59.5363","volume":"33","author":"JG Gribben","year":"2015","unstructured":"Gribben JG, Fowler N, Morschhauser F. Mechanisms of action of Lenalidomide in B-cell non-Hodgkin lymphoma. J Clin Oncol. 2015;33:2803\u201311.","journal-title":"J Clin Oncol"},{"key":"572_CR20","doi-asserted-by":"crossref","unstructured":"\u2022 Catherine Diefenbach M, Brad S. Kahl M, Lalita Banerjee F, et al. Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients With Relapsed\/Refractory Follicular Lymphoma: Primary Analysis of the Full Efficacy Population in a Phase Ib\/II Trial. American Society of Hematology Annual Meeting 2019;Abstract 126. This is the first trial to study a novel triplet combination with pola, anti-CD20 antibody and an immunomodulating agent in R\/R FL, with promising results of tolerability and antitumor activity in the primary analysis of the full efficacy population reported in an abstract format at the 2019 American Society of Hematology annual conference.","DOI":"10.1182\/blood-2019-123669"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-020-00572-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-020-00572-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-020-00572-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,14]],"date-time":"2021-03-14T00:46:36Z","timestamp":1615682796000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-020-00572-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,14]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["572"],"URL":"https:\/\/doi.org\/10.1007\/s11899-020-00572-7","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,14]]},"assertion":[{"value":"14 March 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"CD: Consulting and research funding: Roche\/Genentech. The authors declare no other conflict of interest that is relevant to this review article","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"CD participated in one of the studies referenced in the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}